Back to Search
Start Over
Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study
- Source :
- Arthritis and Rheumatology, Vol. 70, No 11 (2018) pp. 1829-1834, ARTHRITIS & RHEUMATOLOGY, r-FISABIO. Repositorio Institucional de Producción Científica, instname, r-FISABIO: Repositorio Institucional de Producción Científica, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
- Publication Year :
- 2018
-
Abstract
- ObjectiveMethodsData on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database. Adult SSc patients with data on smoking history and a 12-24-month follow-up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses. ResultsConclusionA total of 3,319 patients were included (mean age 57 years, 85% female); 66% were never smokers, 23% were ex-smokers, and 11% were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31% versus 40% and 45%, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio than previous and current smokers (P < 0.001). The FEV1/FVC ratio declined faster in current smokers than in never smokers (P = 0.05) or ex-smokers (P = 0.01). The baseline modified Rodnan skin thickness score (MRSS) and the MRSS decline were comparable across smoking groups. Although heavy smoking (>25 pack-years) increased the odds of digital ulcers by almost 50%, there was no robust adverse association of smoking with digital ulcer development. The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc-specific pulmonary or cutaneous manifestations were not observed.
- Subjects :
- Male
Vital capacity
systemic sclerosis
Vital Capacity
Severity of Illness Index
Scleroderma
0302 clinical medicine
Forced Expiratory Volume
Immunology and Allergy
DNA Topoisomerases/immunology
Longitudinal Studies
skin and connective tissue diseases
Lung
Skin
ddc:616
Smokers
integumentary system
Smoking
Middle Aged
Disease Progression
Female
Autoantibodies/immunology
Adult
medicine.medical_specialty
Skin/pathology
Immunology
03 medical and health sciences
FEV1/FVC ratio
Rheumatology
Internal medicine
Severity of illness
medicine
Humans
Adverse effect
Systemic sclerosis
organ manifestations
prevalence
progression
smoking
Autoantibodies
Aged
030203 arthritis & rheumatology
Scleroderma, Systemic
Heavy smoking
Group study
business.industry
Systemic/immunology/pathology/physiopathology
Lung/physiopathology
Non-Smokers
medicine.disease
respiratory tract diseases
Institutional repository
stomatognathic diseases
Logistic Models
030228 respiratory system
Linear Models
business
Ex-Smokers
Smoking/immunology/pathology/physiopathology
DNA Topoisomerases
Subjects
Details
- Language :
- English
- ISSN :
- 23265191
- Database :
- OpenAIRE
- Journal :
- Arthritis and Rheumatology, Vol. 70, No 11 (2018) pp. 1829-1834, ARTHRITIS & RHEUMATOLOGY, r-FISABIO. Repositorio Institucional de Producción Científica, instname, r-FISABIO: Repositorio Institucional de Producción Científica, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
- Accession number :
- edsair.doi.dedup.....10df3715b69aae92e79eb9109f8421f6